TLX400 / Telix - LARVOL DELTA

Telix Announces Record-Breaking Presence at EANM 2025 (PRNewswire) - "'Telix presentation highlights include the Phase 3 ProstACT Global trial of TLX591 in mCRPC, the IPAX-Linz and IPAX-2 therapeutic trials of TLX101 in glioma, and real-world experience with TLX250-CDx in ccRCC. Telix will host a sponsored symposium on CAIX and FAP targeting theranostics, and abstracts will also be presented from Telix's pan-tumor programs and its Rhine Pharma subsidiary, whose mission is to expand global access to innovative cancer imaging and therapy.'"

Clinical data • Preclinical • Trial status • Castration-Resistant Prostate Cancer • Glioblastoma • Ovarian Cancer • Renal Cell Carcinoma • Triple Negative Breast Cancer